Neil F. McFarlane net worth and biography

Neil McFarlane Biography and Net Worth

President & Chief Executive Officer of Zevra Therapeutics

Neil F. McFarlane has served as our president, chief executive officer, and a director of our Company since October 2023. Mr. McFarlane served as a member of the board of directors of Collegium Pharmaceutical Inc. between April 2022 and July 2024. Previously, Mr. McFarlane served as the chief executive officer and a member of the board of directors of Adamas Pharmaceuticals, Inc. from September 2019 until its acquisition by Supernus Pharmaceuticals, Inc. in November 2021. Mr. McFarlane worked as an independent consultant between June 2019 and August 2019 and again between December 2021 and September 2023 providing consulting services for biotechnology, pharmaceutical, and financial services companies. From August 2016 to May 2019, Mr. McFarlane served as the chief operating officer of Retrophin, Inc., now known as Travere Therapeutics, Inc., where he was responsible for overseeing operations. From 2011 to 2016 Mr. McFarlane served as vice president and general manager of UCB, Inc.’s U.S. Immunology Business Unit and as vice president for its Global Bone Business Unit in collaboration with Amgen Inc. Prior to his positions at UCB, Mr. McFarlane held positions of increasing responsibility with Genzyme Corporation (“Genzyme”) and Sangstat Medical Corporation prior to its acquisition by Genzyme. Mr. McFarlane previously served as an officer and enlisted soldier in the United States Army Reserves. He received his B.S. degree and M.S. degree in Nursing from the University of Florida. Our Board believes that Mr. McFarlane’s over 20 years of global biopharmaceutical and life sciences experience provide him with the qualifications and skills to serve as a director.

What is Neil F. McFarlane's net worth?: The estimated net worth of Neil F. McFarlane is at least $1.92 million as of October 10th, 2025. Mr. McFarlane owns 222,016 shares of Zevra Therapeutics stock worth more than $1,922,659 as of December 5th. This net worth estimate does not reflect any other assets that Mr. McFarlane may own. Additionally, Mr. McFarlane receives an annual salary of $503,770.00 as President & Chief Executive Officer at Zevra Therapeutics. Learn More about Neil F. McFarlane's net worth.
How old is Neil F. McFarlane?: Mr. McFarlane is currently 51 years old. There are 6 older executives and no younger executives at Zevra Therapeutics. The oldest executive at Zevra Therapeutics is Mr. Rahsaan W. Thompson J.D., Chief Legal Officer, Secretary & Compliance Officer, who is 53 years old. Learn More on Neil F. McFarlane's age.
What is Neil F. McFarlane's salary?: As the President & Chief Executive Officer of Zevra Therapeutics, Inc., Mr. McFarlane earns $503,770.00 per year. There are 3 executives that earn more than Mr. McFarlane. The highest earning executive at Zevra Therapeutics is Mr. Joshua M. Schafer M.B.A., Chief Commercial Officer & Executive VP of Business Development, who commands a salary of $766,070.00 per year. Learn More on Neil F. McFarlane's salary.
How do I contact Neil F. McFarlane?: The corporate mailing address for Mr. McFarlane and other Zevra Therapeutics executives is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. Zevra Therapeutics can also be reached via phone at (321) 939-3416 and via email at [email protected]. Learn More on Neil F. McFarlane's contact information.
Has Neil F. McFarlane been buying or selling shares of Zevra Therapeutics?: During the last quarter, Neil F. McFarlane has sold $210,990.00 in Zevra Therapeutics stock. Most recently, Neil F. Mcfarlane sold 19,500 shares of the business's stock in a transaction on Friday, October 10th. The shares were sold at an average price of $10.82, for a transaction totalling $210,990.00. Following the completion of the sale, the chief executive officer now directly owns 222,016 shares of the company's stock, valued at $2,402,213.12. Learn More on Neil F. McFarlane's trading history.
Who are Zevra Therapeutics' active insiders?: Zevra Therapeutics' insider roster includes Thomas Anderson (Director), John Bode (Director), R. Clifton (Chief Financial Officer & Treasurer), Neil McFarlane (President & Chief Executive Officer), Timothy Sangiovanni (Senior Vice President, Corporate Controller), Joshua Schafer (Chief Commercial Officer), and Corey Watton (Director). Learn More on Zevra Therapeutics' active insiders.
Are insiders buying or selling shares of Zevra Therapeutics?: In the last year, Zevra Therapeutics insiders bought shares 4 times. They purchased a total of 18,475 shares worth more than $152,485.25. In the last year, insiders at the sold shares 5 times. They sold a total of 105,273 shares worth more than $885,165.78. The most recent insider tranaction occured on October, 10th when CEO Neil F Mcfarlane sold 19,500 shares worth more than $210,990.00. Insiders at Zevra Therapeutics own 2.4% of the company. Learn More about insider trades at Zevra Therapeutics.
Information on this page was last updated on 10/10/2025.

Neil F. McFarlane Insider Trading History at Zevra Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/10/2025	Sell	19,500	$10.82	$210,990.00	222,016
2/13/2025	Sell	61,273	$7.86	$481,605.78	222,060

Neil F. McFarlane Buying and Selling Activity at Zevra Therapeutics

Zevra Therapeutics Company Overview

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Today's Range

Now: $8.66

$8.48

$8.80

50 Day Range

MA: $9.79

$8.17

$11.78

2 Week Range

Now: $8.66

$6.19

$13.16

Volume

823,188 shs

Average Volume

1,395,027 shs

Market Capitalization

$487.56 million

P/E Ratio

18.43

Dividend Yield

N/A

Beta

1.01

Neil McFarlane Biography and Net Worth

What is Neil F. McFarlane's net worth?

How old is Neil F. McFarlane?

What is Neil F. McFarlane's salary?

How do I contact Neil F. McFarlane?

Has Neil F. McFarlane been buying or selling shares of Zevra Therapeutics?

Who are Zevra Therapeutics' active insiders?

Are insiders buying or selling shares of Zevra Therapeutics?